AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. on December 11, 2020, reporting events occurring on December 8, 2020. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "AIM".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved significant compensation adjustments effective January 1, 2021, for two key officers:
- Peter Rodino (COO, General Counsel, Secretary): Base annual salary increased by $25,000 to $425,000. Received a $130,000 bonus and options to purchase 75,000 shares of common stock (10-year term).
- Ellen Lintal (CFO): Base annual salary increased by $100,000 to $350,000. Received a $100,000 bonus and options to purchase 75,000 shares of common stock (10-year term).
These adjustments were recommended by the Compensation Committee with input from an independent advisor, citing recent company accomplishments.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, risk factors, or discussion of contingencies. The compensation increases are based on past accomplishments rather than future performance targets.
Key Facts for Investor Verification
- Verify the total cash compensation impact ($355,000 in immediate bonuses and $125,000 in annual salary increases) against the company's current cash reserves.
- Confirm the valuation and exercise price of the 150,000 total stock options granted to the executives.
- Review the company's recent financial statements to assess the impact of these increased fixed costs on future burn rates.